Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
IL-17C is a functionally distinct member of the IL-17 family that binds IL-17 receptor E/A to promote innate defense in epithelial cells and regulate Th17 cell differentiation. We demonstrate that IL-17C (not IL-17A) is the most abundant IL-17 isoform in lesional psoriasis skin (1058 versus 8 pg/ml; p < 0.006) and localizes to keratinocytes (KCs), endothelial cells (ECs), and leukocytes. ECs stimulated with IL-17C produce increased TNF-α and KCs stimulated with IL-17C/TNF-α produce similar inflammatory gene response patterns as those elicited by IL-17A/TNF-α, including increases in IL-17C, TNF-α, IL-8, IL-1α/β, IL-1F5, IL-1F9, IL-6, IL-19, CCL20, S100A7/A8/A9, DEFB4, lipocalin 2, and peptidase inhibitor 3 (p < 0.05), indicating a positive proinflammatory feedback loop between the epidermis and ECs. Psoriasis patients treated with etanercept rapidly decrease cutaneous IL-17C levels, suggesting IL-17C/TNF-α-mediated inflammatory signaling is critical for psoriasis pathogenesis. Mice genetically engineered to overexpress IL-17C in KCs develop well-demarcated areas of erythematous, flakey involved skin adjacent to areas of normal-appearing uninvolved skin despite increased IL-17C expression in both areas (p < 0.05). Uninvolved skin displays increased angiogenesis and elevated S100A8/A9 expression (p < 0.05) but no epidermal hyperplasia, whereas involved skin exhibits robust epidermal hyperplasia, increased angiogenesis and leukocyte infiltration, and upregulated TNF-α, IL-1α/β, IL-17A/F, IL-23p19, vascular endothelial growth factor, IL-6, and CCL20 (p < 0.05), suggesting that IL-17C, when coupled with other proinflammatory signals, initiates the development of psoriasiform dermatitis. This skin phenotype was significantly improved following 8 wk of TNF-α inhibition. These findings identify a role for IL-17C in skin inflammation and suggest a pathogenic function for the elevated IL-17C observed in lesional psoriasis skin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“IL-17C can drive psoriatic inflammation in mouse models”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Johnston et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogenesis and therapy of psoriasis
Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007) · Nature · doi:10.1038/nature05663 · Cited by 1,778
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Functional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
Etanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D., & Banerjee, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109997 · Cited by 936
Nograles, K. E., Zaba, L. C., Guttman-Yassky, E., Fuentes-Duculan, J., Suárez-Fariñas, M., Cardinale, I., Khatcherian, A., Gonzalez, J., Pierson, K. C., White, T. R., et al. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08769.x · Cited by 804
Chiricozzi, A., Guttman-Yassky, E., Suárez-Fariñas, M., Nograles, K. E., Tian, S., Cardinale, I., Chimenti, S., & Krueger, J. G. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.340 · Cited by 686
IL-17C regulates the innate immune function of epithelial cells in an autocrine manner
Ramirez-Carrozzi, V., Sambandam, A., Luis, E., Lin, Z., Jeet, S., Lesch, J., Hackney, J., Kim, J., Zhou, M., Lai, J., et al. (2011) · Nature Immunology · doi:10.1038/ni.2156 · Cited by 477
A Randomized Trial of Etanercept as Monotherapy for Psoriasis
Gottlieb, A. B. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.12.1627 · Cited by 470
Research works printed but not linked: 1
- Russell, 2012, IL-17 Receptor A subunit is a central hub for inflammatory signaling in human psoriasis, J. Invest. Dermatol., 132, S7
Cited by
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32549-6 · Cited by 2,383
Self-citationThe IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443
“, 2015), and IL-17C can drive psoriatic inflammation in mouse models (Johnston et al., 2013; Ramirez-Carrozzi et al., 2011).”
BackgroundPhase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503824 · Cited by 828
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Blauvelt, A., & Chiricozzi, A. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-018-8702-3 · Cited by 789
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00184-7 · Cited by 668
Advances in the pathogenesis of psoriasis: from keratinocyte perspective
Zhou, X., Chen, Y., Cui, L., Shi, Y., & Guo, C. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04523-3 · Cited by 632
IL-17 family: Cytokines, receptors and signaling
Gu, C., Wu, L., & Li, X. (2013) · Cytokine · doi:10.1016/j.cyto.2013.07.022 · Cited by 595
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
Brembilla, N. C., Senra, L., & Boehncke, W.-H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01682 · Cited by 475
Papp, K. A., Reich, K., Paul, C., Blauvelt, A., Baran, W., Bolduc, C., Toth, D., Langley, R. G., Cather, J., Gottlieb, A. B., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14493 · Cited by 470
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Liu, T., Li, S., Ying, S., Tang, S., Ding, Y., Li, Y., Qiao, J., & Fang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594735 · Cited by 386
Baliwag, J., Barnes, D. H., & Johnston, A. (2015) · Cytokine · doi:10.1016/j.cyto.2014.12.014 · Cited by 373
Self-citationCytokinocytes: the diverse contribution of keratinocytes to immune responses in skin
Jiang, Y., Tsoi, L. C., Billi, A. C., Ward, N. L., Harms, P. W., Zeng, C., Maverakis, E., Kahlenberg, J. M., & Gudjonsson, J. E. (2020) · JCI Insight · doi:10.1172/jci.insight.142067 · Cited by 348
Self-citationThe Immunology of Psoriasis-Current Concepts in Pathogenesis
Sieminska, I., Pieniawska, M., & Grzywa, T. M. (2024) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-024-08991-7 · Cited by 346
“In lesional skin, the level of IL-17 family members, especially IL-17A, IL-17C, and IL-17F, is potently upregulated [25, 40, 80, 115–118].”
BackgroundMonin, L., & Gaffen, S. L. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028522 · Cited by 339
Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
Lynde, C. W., Poulin, Y., Vender, R., Bourcier, M., & Khalil, S. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.12.036 · Cited by 335
Reich, K., Papp, K. A., Blauvelt, A., Langley, R. G., Armstrong, A., Warren, R. B., Gordon, K. B., Merola, J. F., Okubo, Y., Madden, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00125-2 · Cited by 315
Di Meglio, P., Villanova, F., & Nestle, F. O. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015354 · Cited by 317
Interleukin-17A and Keratinocytes in Psoriasis
Furue, M., Furue, K., Tsuji, G., & Nakahara, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041275 · Cited by 300
Gordon, K. B., Foley, P., Krueger, J. G., Pinter, A., Reich, K., Vender, R., Vanvoorden, V., Madden, C., White, K., Cioffi, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00126-4 · Cited by 295
Brunner, P. M., Suárez-Fariñas, M., He, H., Malik, K., Wen, H.-C., Gonzalez, J., Chan, T. C.-C., Estrada, Y., Zheng, X., Khattri, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09207-z · Cited by 260
IL-36γ (IL-1F9) Is a Biomarker for Psoriasis Skin Lesions
D'Erme, A. M., Wilsmann-Theis, D., Wagenpfeil, J., Hölzel, M., Ferring-Schmitt, S., Sternberg, S., Wittmann, M., Peters, B., Bosio, A., Bieber, T., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.532 · Cited by 252
Old and New Biological Therapies for Psoriasis
Rønholt, K., & Iversen, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112297 · Cited by 240
Diverse functional roles of lipocalin-2 in the central nervous system
Jha, M. K., Lee, S., Park, D. H., Kook, H., Park, K.-G., Lee, I.-K., & Suk, K. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.12.006 · Cited by 195
Zhang, L.-J., Sen, G. L., Ward, N. L., Johnston, A., Chun, K., Chen, Y., Adase, C., Sanford, J. A., Gao, N., Chensee, M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.021 · Cited by 191
Self-citationAetiology and pathogenesis of hidradenitis suppurativa
Wolk, K., Join‐Lambert, O., & Sabat, R. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19556 · Cited by 192
IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms
Ha, H.-L., Wang, H., Pisitkun, P., Kim, J.-C., Tassi, I., Tang, W., Morasso, M. I., Udey, M. C., & Siebenlist, U. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400513111 · Cited by 171
IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases
Song, X., & Qian, Y. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.07.021 · Cited by 162
Russell, C. B., Rand, H., Bigler, J., Kerkof, K., Timour, M., Bautista, E., Krueger, J. G., Salinger, D. H., Welcher, A. A., & Martin, D. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301737 · Cited by 160
IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa
Fletcher, J. M., Moran, B., Petrasca, A., & Smith, C. M. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13449 · Cited by 154
Skin Immunity to Candida albicans
Kashem, S. W., & Kaplan, D. H. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.007 · Cited by 147
Sangiovanni, E., Fumagalli, M., Pacchetti, B., Piazza, S., Magnavacca, A., Khalilpour, S., Melzi, G., Martinelli, G., & Dell’Agli, M. (2019) · Phytotherapy Research · doi:10.1002/ptr.6400 · Cited by 167
Papp, K. A., Weinberg, M. A., Morris, A., & Reich, K. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00440-2 · Cited by 164
Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
Ashique, S., Bhowmick, M., Pal, R., Khatoon, H., Kumar, P., Sharma, H., Garg, A., Kumar, S., & Das, U. (2024) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2024.100114 · Cited by 139
Nishida, A., Hidaka, K., Kanda, T., Imaeda, H., Shioya, M., Inatomi, O., Bamba, S., Kitoh, K., Sugimoto, M., & Andoh, A. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000654 · Cited by 145
Models in the Research Process of Psoriasis
Bocheńska, K., Smolińska, E., Moskot, M., Jakóbkiewicz-Banecka, J., & Gabig-Cimińska, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122514 · Cited by 132
Mease, P. J., Helliwell, P. S., Hjuler, K. F., Raymond, K., & McInnes, I. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216835 · Cited by 131
Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies
Bugaut, H., & Aractingi, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.621956 · Cited by 151
TH17 cells and corticosteroid insensitivity in severe asthma
Xie, Y., Abel, P. W., Casale, T. B., & Tu, Y. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.12.769 · Cited by 151
Müller, A., Hennig, A., Lorscheid, S., Grondona, P., Schulze‐Osthoff, K., Hailfinger, S., & Kramer, D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801377115 · Cited by 140
The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity
Song, X., He, X., Li, X., & Qian, Y. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.105 · Cited by 137
Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data
Sakkas, L. I., & Bogdanos, D. P. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.09.015 · Cited by 141
Menter, A., Krueger, G. G., Paek, S. Y., Kivelevitch, D. N., Adamopoulos, I. E., & Langley, R. G. B. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00483-2 · Cited by 141
Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis
Jeon, C., Sekhon, S., Yan, D., Afifi, L., Nakamura, M., & Bhutani, T. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1356498 · Cited by 120
Vandeghinste, N., Klattig, J., Jagerschmidt, C., Lavazais, S., Marsais, F., Haas, J. D., Auberval, M., Lauffer, F., Moran, T., Ongenaert, M., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.01.036 · Cited by 115
IL-17-mediated antifungal defense in the oral mucosa is independent of neutrophils
Trautwein-Weidner, K., Gladiator, A., Nur, S., Diethelm, P., & LeibundGut‐Landmann, S. (2014) · Mucosal Immunology · doi:10.1038/mi.2014.57 · Cited by 124
Crosstalk: keratinocytes and immune cells in psoriasis
Kamata, M., & Tada, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1286344 · Cited by 110
Animal models of psoriasis—highlights and drawbacks
Schön, M. P., Manzke, V. S., & Erpenbeck, L. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.034 · Cited by 116
Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer
Brevi, A., Cogrossi, L. L., Grazia, G., Masciovecchio, D., Impellizzieri, D., Lacanfora, L., Grioni, M., & Bellone, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.565470 · Cited by 121
The Role of IL-17 Cytokines in Psoriasis
Mosca, M., Hong, J., Hadeler, E., Hakimi, M., Liao, W. J., & Bhutani, T. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s240891 · Cited by 127
Type1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis
Zhang, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01440 · Cited by 102
Brembilla, N. C., & Boehncke, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1186455 · Cited by 103
T cell mediated pathogenesis in EAE: Molecular mechanisms
Kurschus, F. C. (2015) · Biomedical Journal · doi:10.4103/2319-4170.155590 · Cited by 103
IL-17C/IL-17RE: Emergence of a Unique Axis in TH17 Biology
Nies, J. F., & Panzer, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00341 · Cited by 104
Keratinocyte-Derived IL-17E Contributes to Inflammation in Psoriasis
Senra, L., Stalder, R., Martínez, D. Á., Chizzolini, C., Boehncke, W., & Brembilla, N. C. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.06.009 · Cited by 103
Interleukin-17 family members in health and disease
Chung, S.-H., Ye, X.-Q., & Iwakura, Y. (2021) · International Immunology · doi:10.1093/intimm/dxab075 · Cited by 106
Updated Perspectives on Keratinocytes and Psoriasis: Keratinocytes are More Than Innocent Bystanders
Ortiz‐López, L. I., Choudhary, V., & Bollag, W. B. (2022) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s327310 · Cited by 109
The role of interleukin-17 in asthma: a protective response?
Hynes, G., & Hinks, T. (2020) · ERJ Open Research · doi:10.1183/23120541.00364-2019 · Cited by 103
Lu, H., Hong, T., Jiang, Y., Whiteway, M., & Zhang, S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114960 · Cited by 89
Prinz, I., Sandrock, I., & Mrowietz, U. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20191397 · Cited by 91
Psoriasis and the TNF/IL23/IL17 axis
Furue, K., Ito, T., Tsuji, G., Kadono, T., & Furue, M. (2019) · Giornale Italiano di Dermatologia e Venereologia · doi:10.23736/s0392-0488.18.06202-8 · Cited by 82
MCPIP1/Regnase-1 Restricts IL-17A- and IL-17C-Dependent Skin Inflammation
Monin, L., Gudjonsson, J. E., Childs, E. E., Amatya, N., Xing, X., Verma, A. H., Coleman, B. M., Garg, A. V., Killeen, M., Mathers, A., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601551 · Cited by 82
“Elevated levels of IL-17A and IL-17C occur in lesional human psoriasis skin samples (14, 39, 42), and human KCs FIGURE 3.”
BackgroundInfluentialSelf-citationUnmet Needs in the Field of Psoriasis: Pathogenesis and Treatment
Boehncke, W., & Brembilla, N. C. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8634-3 · Cited by 93
Schafer, P. H., Chen, P., Fang, L., Wang, A., & Chopra, R. (2015) · Journal of Immunology Research · doi:10.1155/2015/906349 · Cited by 82
Friedrich, M., Diegelmann, J., Schauber, J., Auernhammer, C. J., & Brand, S. (2014) · Mucosal Immunology · doi:10.1038/mi.2014.124 · Cited by 90
Murine models of psoriasis and their usefulness for drug discovery
Chuang, S.-Y., Lin, C.-H., Sung, C. T., & Fang, J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1463214 · Cited by 89
Immune responses and therapeutic options in psoriasis
Afonina, I. S., Nuffel, E. V., & Beyaert, R. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03726-1 · Cited by 89
The female-biased factor VGLL3 drives cutaneous and systemic autoimmunity
Billi, A. C., Gharaee‐Kermani, M., Fullmer, J. M., Tsoi, L. C., Hill, B., Gruszka, D., Ludwig, J., Xing, X., Estadt, S. N., Wolf, S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127291 · Cited by 81
Self-citationIL-1 Family Antagonists in Mouse and Human Skin Inflammation
Martin, P., Goldstein, J. D., Mermoud, L., Díaz-Barreiro, A., & Palmer, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652846 · Cited by 84
Guttman‐Yassky, E., & Krueger, J. G. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.02.037 · Cited by 80
The Role of IL-17 Cytokines in Psoriasis
Mosca, M., Hong, J. J., Hadeler, E. K., Hakimi, M., Liao, W. J., & Bhutani, T. (2021) · Dove Medical Press (Taylor and Francis Group) · Cited by 73
Research Techniques Made Simple: Murine Models of Human Psoriasis
Hawkes, J. E., Aðalsteinsson, J. A., Gudjonsson, J. E., & Ward, N. L. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.10.013 · Cited by 71
Self-citationMuromoto, R., Hirao, T., Tawa, K., Hirashima, K., Kon, S., Kitai, Y., & Matsuda, T. (2016) · International Immunology · doi:10.1093/intimm/dxw011 · Cited by 76
Pasquali, L., Srivastava, A., Meisgen, F., Mahapatra, K. D., Xia, P., Landen, N. X. L. N. X., Pivarcsi, A., & Sonkoly, E. (2018) · Acta Dermato Venereologica · doi:10.2340/00015555-3066 · Cited by 76
IL‐17A, IL‐22, IL‐6, and IL‐21 Serum Levels in Plaque‐Type Psoriasis in Brazilian Patients
de Oliveira, P. S. S., Cardoso, P. R. G., Lima, E. V. D. A., Pereira, M. C., Duarte, Â. L. B. P., Pitta, I. D. R., Rêgo, M. J. B. D. M., & Pitta, M. G. D. R. (2015) · Mediators of Inflammation · doi:10.1155/2015/819149 · Cited by 77
Friedrich, M., Tillack, C., Wollenberg, A., Schauber, J., & Brand, S. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000198 · Cited by 82
Th17 Differentiation and Their Pro-inflammation Function
Song, X., Gao, H., & Qian, Y. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-9487-9_5 · Cited by 74
The role of IL-17 in psoriasis
Malakouti, M., Brown, G. E., Wang, E., Koo, J. Y. M., & Levin, E. C. (2014) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.879093 · Cited by 81
Kanemaru, K., Matsuyuki, A., Nakamura, Y., & Fukami, K. (2015) · Experimental Dermatology · doi:10.1111/exd.12691 · Cited by 79
Kusagaya, H., Fujisawa, T., Yamanaka, K., Mori, K., Hashimoto, D., Enomoto, N., Inui, N., Nakamura, Y., Wu, R., Maekawa, M., et al. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0130oc · Cited by 73
Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis
Tomalin, L. E., Russell, C. B., Garcet, S., Ewald, D. A., Klekotka, P. A., Nirula, A., Norsgaard, H., Suárez‐Fariñas, M., & Krueger, J. G. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.10.041 · Cited by 69
Nadeem, A., Ahmad, S. F., Al-Harbi, N. O., El‐Sherbeeny, A. M., Al‐Harbi, M. M., & Almukhlafi, T. S. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.02.014 · Cited by 66
Tollenaere, M. A. X., Hebsgaard, J. B., Ewald, D. A., Lovato, P., Garcet, S., Li, X., Pilger, S., Tiirikainen, M. L., Bertelsen, M., Krueger, J. G., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20090 · Cited by 73
IL-6 Differs from TNF-α: Unpredicted Clinical Effects Caused by IL-6 Blockade in Psoriasis
Blauvelt, A. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.11.022 · Cited by 61
Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis
Baumer, Y., Ng, Q., Sanda, G. E., Dey, A. K., Teague, H., Sorokin, A. V., Dagur, P. K., Silverman, J. I. M., Harrington, C. L., Rodante, J. A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97179 · Cited by 69
Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation
Peng, T., Chanthaphavong, R. S., Sun, S., Trigilio, J. A., Phasouk, K., Jin, L., Layton, E. D., Li, A. Z., Correnti, C. E., De van der Schueren, W., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160581 · Cited by 60
A GRHL3-regulated repair pathway suppresses immune-mediated epidermal hyperplasia
Gordon, W. M., Zeller, M. D., Klein, R. H., Swindell, W. R., Ho, H., Espetia, F., Gudjonsson, J. E., Baldi, P., & Andersen, B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci77138 · Cited by 64
Self-citationEffect of IL-17 receptor A blockade with brodalumab in inflammatory diseases
Nirula, A., Nilsen, J., Klekotka, P. A., Kricorian, G., Erondu, N., Towne, J. E., Russell, C. B., Martin, D. A., & Budelsky, A. (2016) · Rheumatology · doi:10.1093/rheumatology/kew346 · Cited by 63
Conti, H. R., Whibley, N., Coleman, B. M., Garg, A. V., Jaycox, J. R., & Gaffen, S. L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122807 · Cited by 57
Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action
Noor, A. A. M., Azlan, M., & Redzwan, N. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020498 · Cited by 66
Johnston, A. W. B., Guzman, A. M., Swindell, W. R., Wang, F., Kang, S., & Gudjonsson, J. E. (2014) · British Journal of Dermatology · doi:10.1111/bjd.12937 · Cited by 60
Self-citationKlein, R. H., Lin, Z., Hopkin, A. S., Gordon, W., Tsoi, L. C., Liang, Y., Gudjonsson, J. E., & Andersen, B. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006745 · Cited by 56
Self-citationPotestio, L., Martora, F., Lauletta, G., Vallone, Y., Battista, T., & Megna, M. (2024) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s462797 · Cited by 59
Oliver, R., Krueger, J. G., Glatt, S., Vajjah, P., Mistry, C., Page, M., Edwards, H., Garcet, S., Li, X., Dizier, B., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20827 · Cited by 54
Current Medical and Surgical Treatment of Hidradenitis Suppurativa—A Comprehensive Review
Ocker, L., Rached, N. A., Seifert, C., Scheel, C., & Bechara, F. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237240 · Cited by 54
IL‐17C amplifies epithelial inflammation in human psoriasis and atopic eczema
Lauffer, F., Jargosch, M., Baghin, V., Krause, L., Kempf, W., Absmaier-Kijak, M., Morelli, M., Madonna, S., Marsais, F., Lepescheux, L., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16126 · Cited by 54
IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis
Goldstein, J. D., Bassoy, E. Y., Caruso, A., Palomo, J., Rodriguez, E., Lemeille, S., & Gabay, C. (2020) · Life Science Alliance · doi:10.26508/lsa.202000688 · Cited by 58
Fritz, Y., Klenotic, P. A., Swindell, W. R., Yin, Z. Q., Groft, S. G., Zhang, L., Baliwag, J., Camhi, M. I., Diaconu, D., Young, A. B., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.10.021 · Cited by 53
Self-citationNishikawa, H., Taniguchi, Y., Matsumoto, T., Arima, N., Masaki, M., Shimamura, Y., Inoue, K., Horino, T., Fujimoto, S., Ohko, K., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.09.017 · Cited by 53
Epithelial TRAF6 drives IL-17–mediated psoriatic inflammation
Matsumoto, R., Dainichi, T., Tsuchiya, S., Nomura, T., Kitoh, A., Hayden, M. S., Ishii, K. J., Tanaka, M., Honda, T., Egawa, G., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121175 · Cited by 51
Metadata
- Authors
- Johnston, A., Fritz, Y., Dawes, S. M., Diaconu, D., Al-Attar, P. M., Guzman, A. M., Chen, C. S., Fu, W., Gudjonsson, J. E., McCormick, T. S., & Ward, N. L.
- Affiliations
- University of Michigan (US)
- Case Western Reserve University (US)
- University Hospitals of Cleveland (US)
- Corresponding author
- Johnston, Andrew
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-03-01
- Volume
- 190
- Issue
- 5
- Pages
- 2252-2262
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC3577967
- OpenAlex
- W2121900420
- Cited by
- 308
- References
- 37
- Citations by year
- 2026: 6 · 2025: 20 · 2024: 20 · 2023: 22 · 2022: 25 · 2021: 36 · 2020: 29 · 2019: 23 · 2018: 29 · 2017: 24 · 2016: 24 · 2015: 23 · 2014: 19 · 2013: 7
- FWCI
- 13.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50AR055508, P30AR039750, P50AR05508, P30 AR39750, R01AR062546, R01AR063437, K08AR060802)
- Janssen Research and Development
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- IL-17C, psoriasis, keratinocytes, IL-17A, TNF-α, endothelial cells, epidermal hyperplasia, angiogenesis, S100A8/A9, Th17 cells, IL-23, etanercept, anti-TNF therapy, psoriasiform dermatitis
- MeSH terms
- Etanercept, Adolescent, Adult, Aged, Animals, Anti-Inflammatory Agents, Non-Steroidal, Humans, Immunoglobulin G, Inflammation, Mice, Transgenic, Middle Aged, Psoriasis, Skin, Tumor Necrosis Factor-alpha, Signal Transduction, Keratinocytes, Gene Expression, Receptors, Tumor Necrosis Factor, Interleukin-17, Endothelial Cells, Mice, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.